138775-02-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a key intermediate in the synthesis of various drugs, leveraging its protective groups to facilitate the creation of complex molecular structures that are otherwise challenging to produce. (R)-N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID aids in the development of new pharmaceuticals by providing a stable and easily modifiable platform for medicinal chemists to work with.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (R)-N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID serves as a building block for the synthesis of more complex molecules with potential therapeutic applications. Its presence in the synthesis process allows for the exploration of new drug candidates and the enhancement of existing ones, contributing to the advancement of medical treatments.
Used in Organic Synthesis:
(R)-N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is utilized as a protecting group for amines in organic synthesis. This function is crucial for the selective reaction of certain functional groups while preventing others from reacting, thereby controlling the outcome of complex organic reactions and ensuring the desired product is obtained.

InChI:InChI=1/C18H24N2O6/c1-18(2,3)26-17(24)20-10-9-19(11-14(20)15(21)22)16(23)25-12-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,21,22)/t14-/m1/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 276695-09-1 (R)-4-carbobenzyloxypiperazine-2-carboxylic acid 

Downstream Products

• 278790-00-4 piperazine-1,2,4-tricarboxylic acid 4-benzyl ester 1-tert-butyl ester 2-methyl ester 
• 405175-79-3 (R)-4-((benzyloxy)carbonyl)piperazine-2-carboxylic acid 
• 1211400-32-6 (8aR)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1R,2S)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-31-5 C₂₂H₂₅N₃O₃ 
• 1351165-23-5 C₂₂H₂₅N₃O₃ 
• 1211400-33-7 (8aR)-N-(2,3-dichlorophenyl)-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide 
• 1351165-63-3 C₂₁H₂₂Cl₂N₄O₂ 
• 1351165-30-4 C₂₁H₂₂Cl₂N₄O₂ 

Relevant academic research and scientific papers

Solid-phase synthesis and biological evaluation of piperazine-based novel bacterial topoisomerase inhibitors

There is an emerging global need for new and more effective antibiotics against multi-resistant bacteria. This situation has led to massive industrial investigations on novel bacterial topoisomerase inhibitors (NBTIs) that target the vital bacterial enzym

SAR studies on a series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl) piperazine-2-carboxamides: Potent inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

Described herein is the initial optimization of (+/-) N-benzyl-4- heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamide (1), a hit discovered in a high throughput screen run against the NS5B polymerase enzyme of the hepatitis C virus. This effort resulted in the identification of (S)-N-sec-butyl-6-((R)-3- (4-(trifluoromethoxy)benzylcarbamoyl)-4-(4-(trifluoromethoxy)phenylsulfonyl) piperazin-1-yl)pyridazine-3-carboxamide (2), that displayed potent replicon activities against HCV genotypes 1b and 1a (EC50 1b/1a = 7/89 nM).

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

Piperazine compounds as inhibitors of MMP or TNF

A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino; R4is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNFα-mediated diseases.